Day One Biopharmaceuticals’ (DAWN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $36.00 price target on the stock.

A number of other research firms have also issued reports on DAWN. Bank of America reduced their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Wedbush reissued an “outperform” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals has an average rating of “Buy” and a consensus price target of $32.29.

Day One Biopharmaceuticals Trading Down 3.3 %

NASDAQ DAWN opened at $7.71 on Thursday. Day One Biopharmaceuticals has a 12-month low of $7.52 and a 12-month high of $18.07. The company has a fifty day simple moving average of $10.23 and a two-hundred day simple moving average of $12.44. The stock has a market cap of $781.45 million, a P/E ratio of -7.49 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million. As a group, sell-side analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the transaction, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now directly owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock valued at $251,925 over the last quarter. 8.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in Day One Biopharmaceuticals in the fourth quarter valued at $866,000. Charles Schwab Investment Management Inc. raised its holdings in Day One Biopharmaceuticals by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock valued at $7,069,000 after buying an additional 64,700 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in Day One Biopharmaceuticals by 90.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock valued at $1,535,000 after buying an additional 57,601 shares during the last quarter. Geode Capital Management LLC boosted its stake in Day One Biopharmaceuticals by 10.5% during the third quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock worth $19,961,000 after buying an additional 136,458 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of Day One Biopharmaceuticals by 18.4% during the third quarter. Janus Henderson Group PLC now owns 2,177,197 shares of the company’s stock valued at $30,307,000 after acquiring an additional 337,928 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.